Membership

RFP, CGN and CGA Opportunities

The Alliance is a community dedicated to connecting healthcare education professionals to promote best practices that improve patient care. To help achieve this, we collect information on research proposals and grants offered through other healthcare-related organizations. If your company is interested in posting a request for grant applications, please contact the Alliance Business Office at acehp@acehp.org


Alnylam Pharmaceuticals 

Alnylam is committed to supporting global healthcare improvement for patients through the medical and scientific understanding of our therapeutic areas of interest for healthcare professionals. Alnylam is currently accepting submissions in response to the following Requests for Proposals (RFPs).

Proposals must be submitted at https://alnylam-grants.steeprockinc.com

Questions regarding this RFP may be sent to grants@alnylam.com  

Open RFPs:

  • ALNY-ME-RFP-7
    • Identifying and Evaluating Patients at High Risk of Monogenic Kidney Stone Disorders including Primary Hyperoxaluria Type 1 (PH1)
    • Submission Deadline: August 14, 2020
    • Details about this RFP may be found at:

https://www.alnylam.com/about-alnylam/grants-and-giving/independent-medical-education-programs/    or

https://alnylam-grants.steeprockinc.com


Amicus Therapeutics

**UPDATED RFE** (7/14/2020)

Amicus Therapeutics is committed to supporting high quality independent medical education (IME) that narrows unmet educational needs and improves healthcare provider knowledge, competence, and performance. IME supported by Amicus is intended to ultimately improve the outcomes of patients with rare and orphan diseases.

Amicus is posting a Request for Education (RFE) to inform qualified medical education providers that we are currently accepting requests for the following:

Therapeutic Area: Fabry disease

Program Type: Satellite Symposium at ACMG 2021

View Request for Education

Submission Deadline: July 31, 2020

Please visit our website at Amicus Global Medical Affairs to learn more details.


Biogen

Biogen considers requests for independent medical education activities within the disease areas listed below. As areas of interest may change periodically, please consult the Biogen Grants and Giving website (https://grantsandgiving.biogen.com/) for the most up to date information. Please note that the submission and review process for international funding opportunities may differ.

  • Alzheimer’s Disease
  • Amyotrophic Lateral Sclerosis
  • Lupus
  • Multiple Sclerosis
  • Ophthalmology
  • Parkinson’s Disease
  • Spinal Muscular Atrophy

For additional information on the Biogen grant submission process, please visit our website.


Bristol-Myers Squibb

Bristol-Myers Squibb accepts funding requests within the following therapeutic areas of interest. As areas of interest and funding consideration may change periodically, please consult this website frequently. Please note that international funding opportunities may differ.

  • Cardiovascular
  • Immunoscience
  • Oncology
  • Virology
  • Genetically Defined / Rare Diseases

View Request for Proposals / for Education


Daiichi-Sankyo

Request for Proposal (RFP):  Molecular Diagnostics and Emerging Targeted Cancer Therapies for HER2+ Metastatic Breast Cancer: from the clinical value and impact of testing to the utilization of emerging targeted therapies to provide the optimal outcomes to patients with cancer

Posting Date: Week of August 7, 2020

Therapeutic focus

  • HER2+ Metastatic Breast Cancer 
Recommended Learning Format
  • Daiichi Sankyo welcomes all tactical recommendations that demonstrate a reduction in ongoing clinical and learning gaps. During this current time, Daiichi Sankyo may provide a preferential review to virtual and/or digitally interactive certified program(s) that meet (not adds to) the overextended demands clinicians face during COVID-19. 
Recommended Learning Target
  • Global/world-wide academic and community medical oncologists, pathologists, oncology nurses, pharmacists, and other clinical oncology team members, to include regions in Africa, Asia, Australia, Europe, North America (U.S. included), and South America   

Phase 1 Due: August 21, 2020
(Daiichi Sankyo communicates phase 1 decision on September 4)
Phase 2 Due: September 18, 2020
Final grant decision communicated: October 9, 2020
Expected launch date: Between October and December 2020 in order to incorporate all fair/balanced current and emerging information through 2020, inclusive of recent evidence reported at annual oncology conferences (i.e. ASCO, AACR, ESMO, etc.)
 
The Process for the Daiichi Sankyo RFP Submission
Phase 1: Initial Executive Summary to include one-to-two page(s) of a summarized gap analysis and description of the educational design, tactic, implementation, and outcomes plan to be submitted to OGE-CME@dsi.com with the subject line “2020 RFP 20002 [& your personalized title]”
Phase 2: If selected to move forward, you will be invited to expand upon your initial Executive Summary by submitting a complete Grant Request to DSI.com, under “Responsibility,” and “CME Grants,” choosing the appropriate RFP dropdown item when starting the submission process, and then titling your grant as “2020 RFP 20002 [& your personalized title]”
Daiichi Sankyo welcomes all accredited or accredited-partnered educational providers to respond to this request. We ask that educational providers only submit one response to each RFP. All submissions will be reviewed in compliance with our Standard Operating Procedures and policies, impartially without any preset grant decision(s) made at the release of this RFP.

Questions regarding this RFP can be submitted to OGE-CME@dsi.com  

Request for Proposal (RFP):  Molecular Diagnostics and Emerging Targeted Cancer Therapies for HER2+ Metastatic Gastric and/or Colorectal Cancers: from the clinical value and impact of testing to the utilization of emerging targeted therapies to provide the optimal outcomes to patients with cancer

Posting Date: Week of August 7, 2020

Therapeutic focus

  • HER2+ metastatic Gastric and/or Colorectal Cancers 
Recommended Learning Format
  • Daiichi Sankyo welcomes all tactical recommendations that demonstrate a reduction in ongoing clinical and learning gaps. During this current time, Daiichi Sankyo may provide a preferential review to virtual and/or digitally interactive certified program(s) that meet (not adds to) the overextended demands clinicians face during COVID-19. 
Recommended Learning Target
  • Global/world-wide academic and community medical oncologists, pathologists, oncology nurses, pharmacists, and other clinical oncology team members, to include regions in Africa, Asia, Australia, Europe, North America (U.S. included), and South America   

Phase 1 Due: August 21, 2020
(Daiichi Sankyo communicates phase 1 decision on September 4)
Phase 2 Due: September 18, 2020
Final grant decision communicated: October 9, 2020
Expected launch date: Between October and December 2020 in order to incorporate all fair/balanced current and emerging information through 2020, inclusive of recent evidence reported at annual oncology conferences (i.e. ASCO, AACR, ESMO, etc.)
 
The Process for the Daiichi Sankyo RFP Submission
 Phase 1: Initial Executive Summary to include one-to-two page(s) of a summarized gap analysis and description of the educational design, tactic, implementation, and outcomes plan to be submitted to OGE-CME@dsi.com with the subject line “2020 RFP 20002 [& your personalized title]”
 Phase 2: If selected to move forward, you will be invited to expand upon your initial Executive Summary by submitting a complete Grant Request to DSI.com, under “Responsibility,” and “CME Grants,” choosing the appropriate RFP dropdown item when starting the submission process, and then titling your grant as “2020 RFP 20002 [& your personalized title]”
Daiichi Sankyo welcomes all accredited or accredited-partnered educational providers to respond to this request. We ask that educational providers only submit one response to each RFP. All submissions will be reviewed in compliance with our Standard Operating Procedures and policies, impartially without any preset grant decision(s) made at the release of this RFP.

Questions regarding this RFP can be submitted to OGE-CME@dsi.com  

Request for Proposal (RFP):  Molecular Diagnostics and Emerging Targeted Cancer Therapies for HER2+ and HER2 Mutant Metastatic NSCLC: from the clinical value and impact of testing to the utilization of emerging targeted therapies to provide the optimal outcomes to patients with cancer

Posting Date: Week of August 7, 2020

Therapeutic focus

  • HER2+ and HER2 mutant metastatic Non-Small Cell Lung Cancer (NSCLC) 
Recommended Learning Format
  • Daiichi Sankyo welcomes all tactical recommendations that demonstrate a reduction in ongoing clinical and learning gaps. During this current time, Daiichi Sankyo may provide a preferential review to virtual and/or digitally interactive certified program(s) that meet (not adds to) the overextended demands clinicians face during COVID-19. 
Recommended Learning Target
  • Global/world-wide academic and community medical oncologists, pathologists, oncology nurses, pharmacists, and other clinical oncology team members, to include regions in Africa, Asia, Australia, Europe, North America (U.S. included), and South America   

Phase 1 Due: August 21, 2020
(Daiichi Sankyo communicates phase 1 decision on September 4)
Phase 2 Due: September 18, 2020
Final grant decision communicated: October 9, 2020
Expected launch date: Between October and December 2020 in order to incorporate all fair/balanced current and emerging information through 2020, inclusive of recent evidence reported at annual oncology conferences (i.e. ASCO, AACR, ESMO, etc.)
 
The Process for the Daiichi Sankyo RFP Submission
 Phase 1: Initial Executive Summary to include one-to-two page(s) of a summarized gap analysis and description of the educational design, tactic, implementation, and outcomes plan to be submitted to OGE-CME@dsi.com with the subject line “2020 RFP 20002 [& your personalized title]”
 Phase 2: If selected to move forward, you will be invited to expand upon your initial Executive Summary by submitting a complete Grant Request to DSI.com, under “Responsibility,” and “CME Grants,” choosing the appropriate RFP dropdown item when starting the submission process, and then titling your grant as “2020 RFP 20002 [& your personalized title]”
Daiichi Sankyo welcomes all accredited or accredited-partnered educational providers to respond to this request. We ask that educational providers only submit one response to each RFP. All submissions will be reviewed in compliance with our Standard Operating Procedures and policies, impartially without any preset grant decision(s) made at the release of this RFP.

Questions regarding this RFP can be submitted to OGE-CME@dsi.com  

Request for Proposal (RFP):  Identifying and Managing Interstitial Lung Disease (ILD) and Pneumonitis in Patients on Cancer Therapy:  from the clinical value and impact of testing to the utilization of emerging targeted therapies to provide the optimal outcomes to patients with cancer

Posting Date: Week of August 7, 2020

Therapeutic focus

  • “General oncology” grants queue, pan-tumor educational initiative, to include HER2+ metastatic Breast Cancer, HER2+ metastatic Gastric Cancer, HER2+ metastatic Colorectal Cancer, and HER2+ & HER2 mutant metastatic Non-Small Cell Lung Cancers 
Recommended Learning Format
  • Daiichi Sankyo welcomes all tactical recommendations that demonstrate a reduction in ongoing clinical and learning gaps. During this current time, Daiichi Sankyo may provide a preferential review to virtual and/or digitally interactive certified program(s) that meet (not adds to) the overextended demands clinicians face during COVID-19. 
Recommended Learning Target
  • Global/world-wide academic and community medical oncologists, pathologists, oncology nurses, pharmacists, and other clinical oncology team members, to include regions in Africa, Asia, Australia, Europe, North America (U.S. included), and South America   

Phase 1 Due: August 21, 2020
(Daiichi Sankyo communicates phase 1 decision on September 4)
Phase 2 Due: September 18, 2020
Final grant decision communicated: October 9, 2020
Expected launch date: Between October and December 2020 in order to incorporate all fair/balanced current and emerging information through 2020, inclusive of recent evidence reported at annual oncology conferences (i.e. ASCO, AACR, ESMO, etc.)
 
The Process for the Daiichi Sankyo RFP Submission
 Phase 1: Initial Executive Summary to include one-to-two page(s) of a summarized gap analysis and description of the educational design, tactic, implementation, and outcomes plan to be submitted to OGE-CME@dsi.com with the subject line “2020 RFP 20002 [& your personalized title]”
 Phase 2: If selected to move forward, you will be invited to expand upon your initial Executive Summary by submitting a complete Grant Request to DSI.com, under “Responsibility,” and “CME Grants,” choosing the appropriate RFP dropdown item when starting the submission process, and then titling your grant as “2020 RFP 20002 [& your personalized title]”
Daiichi Sankyo welcomes all accredited or accredited-partnered educational providers to respond to this request. We ask that educational providers only submit one response to each RFP. All submissions will be reviewed in compliance with our Standard Operating Procedures and policies, impartially without any preset grant decision(s) made at the release of this RFP.

Questions regarding this RFP can be submitted to OGE-CME@dsi.com  

Eli Lilly and Company

LINK to Lilly Grant Office portal

Required Tool: Lilly RFP Budget Template

Therapeutic area of interest: Endocrine

View Request for Proposal (RFP)


Genentech

Genentech is seeking to support learning initiatives that demonstrate a strategy that evolves knowledge-based medical education into a “healthcare Improvement” initiative that accelerates the awareness and application of evidence-based medicine, resulting in appropriate care for patients and relevant, measurable, clinical outcomes.

Therapeutic area(s) of interest:

  • Non-Malignant Blood Disorders

View Request for Proposal

Genentech is posting a Call for Grants (CGN) in support of IME activities in Early Non-Small Cell Lung Cancer.

2020 Independent Medical Education Call for Grant Notification

Genentech is posting a Call for Grants (CGN) in support of IME activities for Stroke.

2020 Independent Medical Education Call for Grant Notification 

Genentech is posting a Call for Grant Notification (CGN) for Prostate Cancer in support of IME activities.

2020 Independent Medical Education Call for Grant Notification

With increasing complications from COVID-19, we are extending the deadlines associated with the Call for Grant Notification (CGN) in support of education in hepatocellular carcinoma for Hepatologists.

2020 Independent Medical Education Call for Grant Notification

Genentech is posting a Call for Grant Notification (CGN) for Disparities in Care (in TNBC, HCC, and general oncology) in support of IME activities. 

2020 Independent Medical Education Call for Grant Notification

Genentech is posting a Call for Grant Notification (CGN) on June 8, 2020 for General Oncology in support of IME activities.

2020 Independent Medical Education Call for Grant Notification

Genentech is posting a Call for Grant Notification (CGN) on June 12, 2020 for Hemophilia A and Acute Myeloid Leukemia (AML)  in support of IME activities.

2020 Independent Medical Education Call for Grant Notification


Indivior

Indivior supports independent medical education activities that provide for an increased understanding of scientific, clinical, or healthcare issues related to the company’s therapeutic areas of interest. 

Therapeutic areas of interest:

  • Opioid Use Disorder
  • Schizophrenia

To view open RFPs and complete details regarding grant submission, please visit the following site on a regular basis: grants.indivior.com


Insmed Incorporated

Insmed has funding to support independent accredited education intended to improve clinician knowledge, competence, and performance in the diagnosis and treatment of patients with Nontuberculous Mycobacterial (NTM) Lung Disease. Please refer to https://insmed.com/culture/responsibility/ for grant submission requirements. For additional questions about the CGA process please contact Insmed Medical Education at grants@insmed.com. Grant submissions should align to the specifications in the downloadable CGA.

Therapeutic Areas: Pulmonology/Infectious Disease
Nontuberculous Mycobacterial (NTM) Lung Disease
Focus Area: Education Activities associated with 2021 CHEST and IDWeek and other Medical Society Conferences

Submission Deadline: September 1, 2020

https://insmed.com/wp-content/uploads/2020/08/2021-Conference-Call-for-Grants-MED-00151-7.16.20.pdf


Medicare Access and CHIP Reauthorization Act of 2015 (MACRA)

The Centers for Medicare & Medicaid Services (CMS) recognizes the benefits of measure development by external stakeholders with specific knowledge of clinician and patient perspectives and needs, such as clinical specialty societies, clinical professional organizations, patient advocacy organizations, educational institutions, independent research organizations, health systems, and other entities. 

On March 2, 2018, CMS published the “Medicare Access and CHIP Reauthorization Act of 2015 (MACRA) Funding Opportunity: Measure Development for the Quality Payment Program” on Grants.gov. The purpose of this Funding Opportunity is to provide technical and funding assistance in the form of cooperative agreements to entities to develop, improve, update, or expand quality measures for use in the Quality Payment Program (QPP). 

For more information and to see the ‘Medicare Access and CHIP Reauthorization Act of 2015 (MACRA) Funding Opportunity: Measure Development for the Quality Payment Program’ search by the title or the Catalog of Federal Domestic Assistance (CFDA) number, 93.986 on Grants.gov.


Novo Nordisk Inc.

Novo Nordisk is committed to supporting independent medical education programs that meet the educational needs of health care professionals (HCPs), patients and the community in ways that measurably grow their knowledge and skills to optimize patient or self care in the following therapeutic areas of interest:

  • Diabetes
  • Obesity

Please visit www.novonordiskgrants.com to apply for educational grants and access the IME Funding Document that provides information about educational priorities and available funding as well as current Request for Proposals (RFPs)/Call for Concept Proposals (CCPs) within these therapeutic areas.


Pfizer Independent Grants for Learning & Change (IGLC)

The mission of Pfizer Independent Grants for Learning & Change is to partner with the global healthcare community to improve patient outcomes in areas of mutual interest through support of measurable learning and change strategies. The Joint Commission is an independent, not-for-profit organization that accredits and certifies nearly 21,000 health care organizations and programs in the United States. 

To view open RFPs and complete details, please visit this webpage.


Regeneron Pharmaceuticals

The Regeneron and Sanofi Genzyme Alliance seeks to close important medical educational gaps with regard to Advanced Basal Cell Carcinoma (BCC) through consideration of grant proposals for 2020-2021 independent medical education activities. Target audiences include Dermato-Oncologist, Oncologists, Dermatologists, Mohs surgeons (US Only), Pharmacists, Registered Nurses, and advanced-level practitioners via live and enduring distribution channels; please refer to the Request for Proposal for further details.


Sanofi Genzyme

Please review and return your completed proposal via the Sanofi U.S. Grant Website at https://sgrants.envisionpharma.com/vt_sgrants/ by 5 p.m. EST on Thursday, September 24, 2020.

If a submission is not completed by this date, your proposal will not be accepted.

When entering proposal into the website, please reference the following:

Therapeutic Area:     Rare Genetic Disease

Area of Interest:        Fabry Disease

RFP Name:                 WORLD 2021

“Please note that an applicant may be ineligible to receive a grant in response to this RFP if the applicant has performed any services under contract with Sanofi U.S. during the last 12 months in connection with:

  • A consultant meeting; or
  • An advisory board meeting

in the same therapeutic area as this request for proposal (“RFP”).

If the applicant has performed such services, please forward a copy of the contract immediately, prior to responding to the RFP, so that we can determine your eligibility.  If not, please acknowledge this in your application writing.”

Please note that you must select the type of activity that you are proposing, i.e., Live, Enduring or Live and Enduring and answer the question, “Are you responding to an RFP” and please select “WORLDS 2021” from the RFP dropdown panel within the grant portal upon submitting your applicant for this RFP.

Submission instructions are available on the website. If you have a content question, please contact Amy Funkhouser at Amy.Funkhouser@sanofi.com.


Shionogi Inc.

Shionogi accepts funding requests within the following therapeutic areas of interest.

  • Gram-negative multidrug-resistant infectious disease (ID)
  • Thrombocytopenia associated with chronic liver disease (CLD)
  • Opioid-induced Constipation (OIC)

The call for grants (CFG) opportunities will change on a quarterly basis.  Please consult our website to identify current opportunities.


TRC Healthcare

TRC Healthcare (TRC), the creators of Pharmacist’s Letter, is committed to helping clinicians and healthcare professionals make safe, effective, and efficient medication decisions.  In support of this mission, TRC is currently accepting submissions in response to the following Requests for Proposals (RFPs).

 

Proposals may be submitted by individuals or groups and are due December 13, 2019.  Please see the individual RFPs for more details.

 

To learn more about TRC, please visit https://trchealthcare.com/about-us/.


UCB, Inc.

UCB, Inc., is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system.

Here are the following open RFPs:

Management of Focal Seizures in Critically ill patients in NCCU/ICU 

RFP release date: August 10th, 2020
Full Proposal Deadline: September 14th, 2020
Please note the deadline is midnight Eastern Time

Please direct any questions that you may have to the UCB Grants Office at grants@ucb.com .